NKGen Biotech’s SNK01 NK Cell Therapy Cleared to Start Phase 2 NKGen Biotech ( NASDAQ:NKGN ), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK natural killer (NK) cell therapeutics, has announced that its Safety Review Committee has cleared the company's cryopreserved autolo